Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop?

Journal of Urology

Volumn 166, Issue 5, 2001, Pages 1679-1683

  Djavan, Bob ^a   Ravery, Vincent ^a   Zlotta, Alex ^a   Dobronski, Piotr ^a   Dobrovits, Michael ^a   Fakhari, Mitra ^a   Seitz, Christian ^a   Susani, Martin ^a   Borkowski, Andrzej ^a   Boccon Gibod, Laurent ^a   Schulman, Claude C ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Neoplasm staging; Prostate specific antigen; Prostatic neoplasms; Reoperation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REOPERATION; SCORING SYSTEM;

EID: 0034796225     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)65652-2     Document Type: Article

References (26)

1. Rietbergen, J. B., Kruger, A. E., Hoedemaeker, R. F. et al: Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol, 160: 2121, 1998
2. Djavan, B., Susani, M., Bursa, B. et al: Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol, 5: 139, 1999
3. Djavan, B., Zlotta, A., Remzi, M. et al: Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol, 163: 1144, 2000
4. Fowler, J. E., Jr., Bigler, S. A., Miles, D. et al: Predictors of first repeat biopsy cancer detection with suspected local prostate cancer. J Urol, 163: 813, 2000
5. Stamey, T. A., McNeal, J. E., Yemoto, C. M. et al: Biological determinants of cancer progression in men with prostate cancer. JAMA, 281: 1395, 1999
6. Djavan, B., Mazal, P., Zlotta, A. R. et al: Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate, 47: 111, 2001
7. Djavan, B., Waldert, M., Zlotta, A. R. et al: Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of the Prospective European Prostate Cancer Detection Study. J Urol, in press
8. Zlotta, A. R., Djavan, B., Roumeguere, T. et al: Transition zone volume on transrectal ultrasonography is more accurate and reproducible than the total prostate volume. Br J Urol, suppl., 80: A926, 1997
9. Djavan, B., Zlotta, A. R., Byttebier, G. et al: Prostate specific antigen density of transition zone for early detection of prostate cancer. J Urol, 160: 411, 1998
10. Catalona, W. J., Partin, A. W., Slawin, K. M. et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 279: 1542, 1998
11. Chan, D. W., Sokoll, L. J., Partin, A. W. et al: The use of % free PSA to predict prostate cancer probabilities: an eleven center prospective study using an automated immunoassay system in a population with non-suspicious DRE. J Urol, suppl., 161: 95, abstract 353, 1999
12. Horninger, W., Reissigl, A., Klocker, H. et al: Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate, 37: 133, 1998
13. Ukimura, O., Durrani, O. and Babaian, R. J.: Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology, 50: 66, 1997
14. Letran, J. L., Blasé, A. B., Loberiza, F. R. et al: Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. J Urol, 160: 426, 1998
15. Morgan, T. O., McLeod, D. G., Leifer, E. S. et al: Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology, suppl., 48: 76, 1996
16. Catalona, W. J., Beiser, J. A. and Smith, D. S.: Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol, 158: 2162, 1997
17. Pound, C. R., Partin, A. W., Eisenberger, M. A. et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
18. Fleshner, N. E., O‘Sullivan, M. and Fair, W. R.: Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol, 158: 505, 1997
19. Keetch, D. W., McMurtry, J. M., Smith, D. S. et al: Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol, 156: 428, 1996
20. Durkan, G. C. and Greene, D. R.: Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? BJU Int, 83: 34, 1999
21. Noguchi, M., Yahara, J., Koga, H. et al: Necessity of repeat biopsies in men for suspected prostate cancer. Int J Urol, 6: 7, 1999
22. Keetch, D. W. and Catalona, W. J.: Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol, 154: 1795, 1995
23. Keetch, D. W., Catalona, W. J. and Smith, D. S.: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol, 151: 1571, 1994
24. Djavan, B., Zlotta, A. R., Kratzik, C. et al: PSA, PSA density, PSA density of transition zone, free to total PSA ratio and PSA velocity for prostate cancer in men with serum PSA of 2.5 to 4.0 ng/mL. Urology, 54: 517, 1999
25. Djavan, B., Zlotta, A. R., Remzi, M. et al: Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology, 54: 846, 1999
26. Djavan, B., Zlotta, A. R., Ekane, S. et al: Is one set of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate volume on cancer yield. Eur Urol, 38: 218, 2000